Invex Therapeutics Ltd has released a press release.
Initial FDA and EMA Advice on Presendin Development
Filed with ASX ·
6ix hasn’t read this filing yet.
Invex Therapeutics Ltd. on 6ix
Earlier from Invex Therapeutics
- Notice of Allowance for Key US Exenatide Patent
- Phase II Clinical Results and Capital Raising Presentation
- Succesful $26 million Share Placement
- Exenatide Meets Key Endpoints in IIH Clinical Trial
- Appendix 4D and Half-year Report
Later from Invex Therapeutics
- Quarterly Report and Appendix 4C
- Quarterly Report and Appendix 4C with appendix
- Invex Provides Development Update
- Investor Presentation
- Chairmans Address to Shareholders and Presentation
Follow Invex Therapeutics into a list and get an email when it puts out news.
Follow Invex Therapeutics